Skip to main content

Hepatitis A Immunisation

Volume 301: debated on Tuesday 25 November 1997

The text on this page has been created from Hansard archive content, it may contain typographical errors.

To ask the Secretary of State for Health what steps his Department has taken to evaluate the risks from gamma globulin used in the preparation of Hepatitis A passive immunisation. [17232]

The marketing authorisation (the licensing) of all medicines throughout the European Union is governed by the Rules Governing Medicinal Products in the European Union, in particular, Council Directive 65/65/EEC.All licensed normal intra-muscular immunoglobulin (used for passive immunisation for Hepatitis A) has been fully evaluated for quality, safety and efficacy. These products have not been associated with the transmission of any infection.